Compare AMPG & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPG | TVGN |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Blank Checks |
| Sector | Telecommunications | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 66.8M |
| IPO Year | N/A | N/A |
| Metric | AMPG | TVGN |
|---|---|---|
| Price | $4.02 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 655.8K | 645.2K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,571,945.00 | N/A |
| Revenue This Year | $168.18 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.47 | N/A |
| 52 Week Low | $1.21 | $0.30 |
| 52 Week High | $4.89 | $1.92 |
| Indicator | AMPG | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.51 | 48.82 |
| Support Level | $3.36 | $0.32 |
| Resistance Level | $3.90 | $0.34 |
| Average True Range (ATR) | 0.35 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 85.22 | 50.31 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.